249 related articles for article (PubMed ID: 19883689)
1. HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice.
Wang S; Han Q; Zhang N; Chen J; Liu Z; Zhang G; Li Z
Immunol Lett; 2010 Jan; 127(2):143-9. PubMed ID: 19883689
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase.
Wang S; Han Q; Zhang G; Zhang N; Li Z; Chen J; Lv Y; Li N; Xing F; Tian N; Zhu Q; Liu Z
Int Immunopharmacol; 2011 Apr; 11(4):406-11. PubMed ID: 21182997
[TBL] [Abstract][Full Text] [Related]
3. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice.
Chen X; Lai J; Pan Q; Tang Z; Yu Y; Zang G
Vaccine; 2010 May; 28(23):3913-9. PubMed ID: 20394723
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
[TBL] [Abstract][Full Text] [Related]
6. H-2 Kd-restricted hepatitis B virus-derived epitope whose specific CD8+ T lymphocytes can produce gamma interferon without cytotoxicity.
Chen A; Wang L; Zhang J; Zou L; Jia Z; Zhou W; Wan Y; Wu Y
J Virol; 2005 May; 79(9):5568-76. PubMed ID: 15827171
[TBL] [Abstract][Full Text] [Related]
7. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
8. Identification of HLA-A*0201-restricted CD8+ T-cell epitope C₆₄₋₇₂ from hepatitis B virus core protein.
Liu Q; Zheng Y; Yu Y; Tan Q; Huang X
Int Immunopharmacol; 2012 Jun; 13(2):141-7. PubMed ID: 22480777
[TBL] [Abstract][Full Text] [Related]
9. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine.
Xu W; Chu Y; Zhang R; Xu H; Wang Y; Xiong S
Virology; 2005 Apr; 334(2):255-63. PubMed ID: 15780875
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice.
Zhuo M; Song L; Tang Y; Dai S; Chen X; Yu Y; Zang G; Tang Z
Mol Med Rep; 2015 Sep; 12(3):3591-3598. PubMed ID: 26004262
[TBL] [Abstract][Full Text] [Related]
11. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
[TBL] [Abstract][Full Text] [Related]
12. [The fusion protein of cytoplasmic transduction peptide (CTP)-HBcAg18-27-Tapasin enhances specific immune response to hepatitis B virus and inhibits viral replication in transgenic mice].
Tang Y; Chen X; Zhou L; Zhuo M; Zang G; Tang Z; Yu Y
Zhonghua Gan Zang Bing Za Zhi; 2014 Jan; 22(1):24-9. PubMed ID: 24721239
[TBL] [Abstract][Full Text] [Related]
13. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of dendritic cell-based immunization against HBV in transgenic mice.
Jiang WZ; Fan Y; Liu X; Zhang YL; Wen JJ; Hao WL; Qian M
Antiviral Res; 2008 Jan; 77(1):50-5. PubMed ID: 17897731
[TBL] [Abstract][Full Text] [Related]
15. Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response.
Yang BF; Zhao HL; Xue C; Xiong XH; Zhang W; Yao XQ; Liu ZM
Vaccine; 2007 May; 25(22):4478-86. PubMed ID: 17467856
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
[TBL] [Abstract][Full Text] [Related]
17. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
18. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
Li X; Yang X; Li L; Liu H; Liu J
Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
[TBL] [Abstract][Full Text] [Related]
20. [Dendritic cells originated from the peripheral blood in chronic hepatitis B patients can induce specific T cell immune response].
Li RB; Chen HS; Xie Y; Fei R; Cong X; Fan CL; Wang SX; Wei L; Wang Y
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):588-91. PubMed ID: 14572332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
